China's Gushengtang Holdings HY revenue rises on offline medical institution expansion

GUSHENGTANG HOLDINGS

28/08/2026 05:25

Overview
China traditional medicine provider's half-year revenue rose 10.6% yr/yr to RMB1.65 bln
Net profit attributable to shareholders rose 44% yr/yr to RMB221 mln
Gross profit and EBITDA also grew, supporting higher profitability

Outlook
Gushengtang plans to deploy $33.1 mln of unspent convertible-bond proceeds on offline medical institution expansion by end-Feb 2029
Top-up placing proceeds retain HK$52.7 mln for online-platform integration, targeted for full use by end-2027

Result Drivers
OFFLINE MEDICAL INSTITUTION EXPANSION - Company said revenue from healthcare solutions increased primarily due to business growth with the expansion of offline medical institutions
PATIENT-VISIT GROWTH – Customer visits increased to 3.16 mln from 2.75 mln, while new customers rose to 491,267 from 452,581
CONVERTIBLE-BOND FAIR VALUE – Other income and gains rose to RMB88.7 mln from RMB17.1 mln, primarily due to fair-value gains on financial instruments including convertible bonds

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 1.65 bln
 
H1 Net Income Attributable
 
RMB 220.70 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for GUSHENGTANG HOLDINGS LIMITED is HK$41.00, about 52.5% above its August 27 closing price of HK$26.88
The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 13 three months ago

Reuters Recommended Reads
Aug 26 - China's Consun Pharmaceutical H1 revenue rises on sales network expansion
Aug 27 - China's Hygeia Healthcare H1 profit rises
Aug 26 - China's Jiangsu says it will support pharmaceutical firms' global M&A, licensing

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)